Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06226220 · ClinicalTrials.gov registry record · NA
Percutaneous Nerve Evaluation Trial Time
A NA study of Overactive Bladder and Urge Incontinence, sponsored by University of Chicago.
- Recruiting
- Registry status
- NA
- Development phase
- 193
- Enrollment target
- 1
- Study location
NCT06226220: Recruiting NA study of Overactive Bladder and Urge Incontinence, sponsored by University of Chicago.
NCT06226220 is a NA study of Overactive Bladder and Urge Incontinence that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 193 participants, roughly in line with the 203-participant average among 46 other Overactive Bladder trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06226220, a NA study of Overactive Bladder and Urge Incontinence, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- NA
- Development phase
- 193 participants
- Enrollment target
- 1
- Study location
Study Summary
Sacral neuromodulation (SNM) was approved by the Food and Drug Administration (FDA) for the treatment of urgency incontinence (UUI) in 1998. One of two trial phase techniques are utilized prior to placement of the implantable pulse generator (IPG) to predict a patient's success with the device: a percutaneous nerve evaluation (PNE) or a stage implantation. Patients who experience a \> 50% improvement in UUI symptoms progress to permanent implantation. PNE offers significant advantages compared to a staged implantation including a single anesthetic and operating room trip. Historically, full implantation rates are only 40-50% following PNE versus 70-90% in women who undergo a staged approach. The lower rate of progression to full implantation after PNE may be attributed to lead migration. Newer data suggest up to 90% of PNE trials lead to full implantation. The investigators hypothesize that shortening PNE trial time to 3 days from 7 days will not result in a lower proportion of PNE trials leading to SNM implantation and may offer less time for lead migration. The investigators aim to perform a multi-center, randomized trial to determine if a 3-day PNE trial is not inferior to a 7-day PNE trial with respect to rates of progression to SNM implantation.
Primary Outcome
Participants with an adequate therapeutic response during percutaneous nerve evaluation (PNE) trial (\>/=50% improvement in urgency urinary incontinence (UUI)/ urgency-frequency (UF) symptoms) will progress onto full SNM implantation
Conditions Studied
Interventions
- PROCEDURE Sacral neuromodulation
Study Locations (1)
Illinois
- University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 193 participants |
| Start Date | 2023-12-10 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
What NCT06226220 shows while recruiting
NCT06226220 is an interventional study that assigns participants to a tested intervention. The registered 193 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 203-participant average among 46 other Overactive Bladder trials with a reported enrollment target.
The record links to 3 conditions, with Overactive Bladder appearing as the primary indexed condition, and to 1 intervention - of which Sacral neuromodulation is the first listed.
NCT06226220 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT06226220 about?
NCT06226220 is a clinical study titled "Percutaneous Nerve Evaluation Trial Time". Sacral neuromodulation (SNM) was approved by the Food and Drug Administration (FDA) for the treatment of urgency incontinence (UUI) in 1998. One of two trial phase techniques are utilized prior to placement of the implantable pulse generator (IPG) to predict a patient's success with the device: a pe...
What is the current status of trial NCT06226220?
This trial is currently recruiting. It is a NA study. The enrollment target is 193 participants. The study started on 2023-12-10. Estimated completion is 2026-12-31.
What conditions does trial NCT06226220 study?
This clinical trial studies the following conditions: Overactive Bladder, Urge Incontinence, Urgency-frequency Syndrome.
What interventions are being tested in trial NCT06226220?
The interventions under investigation include: Sacral neuromodulation (PROCEDURE).
Who is sponsoring clinical trial NCT06226220?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06226220 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Overactive Bladder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06226220's enrollment target sits among peer trials
193 15th of 46 higher than 32 of 46 other Overactive Bladder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Overactive Bladder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Home Versus Office Removal of Percutaneous Nerve Evaluation (PNE) Lead
RECRUITING · NA
-
Sacral Neuromodulation for Male Overactive Bladder (MOAB)
RECRUITING · NA
-
Neuromodulating Cortical Regions Involved in Neurogenic Bladder in MS
RECRUITING · NA
-
A Real World Study of eCoin for Urgency Urinary Incontinence: Post Approval Evaluation (RECIPE)
RECRUITING · NA
-
At-Home Transcutaneous Tibial Nerve Stimulation for Overactive Bladder in Rural Women
RECRUITING · NA
-
Pelvic Health Electrically Evoked Recording (PEER) 2 Study
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03593759 · 194 participants · Phase 3
Cardiac Sarcoidosis Randomized Trial
- NCT05053152 · 194 participants · Phase 2
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
- NCT05156112 · 194 participants · NA
OSA PAP Treatment for Veterans With SUD and PTSD on Residential Treatment Unit
- NCT05351424 · 194 participants · NA
AVI Didactic Experience for Latinx Patient Treatment Adherence and Non-English Speaker Trial Enrollment Study in Rad Onc
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI